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Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data
for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16–23 years) were enrolled in a
randomised, placebo-controlled study of a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2,
and 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling for HPV DNA,
serum anti-HPV testing, and Pap testing, with follow-up biopsy as indicated. A subset of 241 subjects underwent two further years of
follow-up. At 5 years post enrolment, the combined incidence of HPV 6/11/16/18-related persistent infection or disease was reduced
in vaccine-recipients by 96% (two cases vaccine versus 46 placebo). There were no cases of HPV 6/11/16/18-related precancerous
cervical dysplasia or genital warts in vaccine recipients, and six cases in placebo recipients (efficacy¼100%; 95% CI:12–100%).
Through 5 years, vaccine-induced anti-HPV geometric mean titres remained at or above those following natural infection. In
conclusion, a prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease
caused by HPV 6/11/16/18. This duration supports vaccination of adolescents and young adults, which is expected to greatly reduce
the burden of cervical and genital cancers, precancerous dysplasia, and genital warts.
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The human papillomavirus (HPV) family is a heterogeneous group
of epitheliotropic viruses of which more than 100 genotypes have
been fully sequenced to date (de Villiers et al, 2004). The primary
target of HPV infection is the basal cell of the squamous
epithelium. In men and women, anogenital infection with HPV
can manifest itself as any one of a large number of subclinical and
clinical manifestations including anogenital neoplasia, cancer, and
genital warts (Gissmann and zur Hausen, 1980; Jones et al, 1997;
Goodman, 1998; Bosch et al, 2002; Partridge and Koutsky, 2006).
HPV infection is common, with a lifetime risk exceeding 50%
(World Health Organization (WHO, 2004)). The prevalence of
HPV in the general population is estimated between 9 and 13%
worldwide and varies between 1.6 and 25.6% depending on the
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scountry (World Health Organization, 2004; Clifford et al, 2005). A
significant proportion of HPV disease is attributed to four types: 6,
11, 16 and 18. HPV types 16 and 18 cause approximately 70% of all
cervical cancer cases worldwide (Mun ˜oz et al, 2003) and a
significant proportion of vaginal (Daling et al, 2002), vulvar
(Madeleine et al, 1997), anal (Frisch, 2002) penile (Partridge and
Koutsky, 2006), and head and neck cancers (Gillison and
Lowy, 2006). HPV 6 and 11 infections in men and women are
responsible for the great majority of genital wart cases (Wiley et al,
2002) and recurrent respiratory papillomatosis, an aggressive,
highly morbid and occasionally fatal disease manifested as
rapidly growing benign laryngeal tumours that cause airway
obstruction (Somers et al, 1997; Derkay and Darrow, 2000; Green
et al, 2000).
In a recent multinational study conducted in 5455 young women
who reported a lifetime history of four or fewer sexual partners,
nearly one-third had serologic or molecular evidence of infection
with high-risk (oncogenic) HPV types 16 or 18, or low-risk
(nononcogenic) HPV types 6 or 11 (Sattler, for the FUTURE I
Investigators, 2005). Owing to the high observed prevalence of
HPV 6, 11, 16, and 18 and their causative association with
anogenital cancers, dysplasia or genital warts, a prophylactic
vaccine covering these types has the potential to substantially
reduce the burden of clinical HPV disease in both men and
women. Phase III trials conducted in 418000 women have
demonstrated that a three-dose regimen of quadrivalent HPV 6/11/
16/18 L1 virus-like particle (VLP) vaccine was 100% effective in
preventing obligate precancerous lesions of the cervix, vagina, and
vulva in women who were naı ¨ve to HPV 6, 11, 16, or 18 through
completion of the vaccination regimen (Sattler, for the FUTURE I
Investigators, 2005). In addition, prophylactic administration of a
three-dose regimen of the vaccine was 100% effective against
genital warts (Sattler, for the FUTURE I Investigators, 2005). In
these Phase III trials, women were followed for an average of 2
years postvaccination. As the risk of HPV infection is life long,
HPV vaccines must induce long-term protection. Here, we report
quadrivalent vaccine efficacy (VE) and immunogenicity through 5
years following vaccination, representing the longest term evalua-
tion to date of an HPV vaccine.
MATERIALS AND METHODS
Study design
The trial (Merck protocol V501-007) was a Phase II, randomised,
multicentre, double-blind, placebo-controlled study of a quad-
rivalent HPV 6/11/16/18 L1 VLP vaccine. A total of 1158 women
aged 16–23 years were recruited in Brazil, Nordic countries
(Finland, Sweden, Norway), and the USA. The study enrolled
nonpregnant, healthy women who had no prior abnormal Pap
smears, and reported a lifetime history of four or fewer male sex
partners. Among virgins, enrolment was limited to those women
who were X18 years of age and seeking contraception. This study
did not exclude subjects with prior HPV infection. Participants
were asked to use effective contraception during the trial. All
subjects or parents/legal guardians signed informed consents
following review of the protocol procedures. The study was
conducted in conformance with applicable country or local
requirements regarding ethical committee review, informed
consent, and other statutes or regulations regarding the protection
of the rights and welfare of human subjects participating in
biomedical research.
The study evaluated three formulations of a quadrivalent HPV 6/
11/16/18 L1 VLP vaccine. The study included two placebo arms
with different adjuvant doses (225 or 450mg) to provide
appropriate safety comparators for the different vaccine formula-
tions. Efficacy, safety, and tolerability through 3 years have been
described for the three formulations (Villa et al, 2005; Villa et al,
2006). Of the 551 women who were randomised and vaccinated
with either the low-dose formulation (which was subsequently
approved as GARDASIL
s, Merck and Co., Inc., Whitehouse
Station, NJ, USA) or placebo, 241 were enrolled in an extension of
the study to obtain an additional 2 years of follow-up data for
safety, efficacy, and immunogenicity. Eligible for participation in
the extension were all subjects from Brazil and the Nordic
countries who had participated in the dose-ranging study, had
been vaccinated with either the low-dose vaccine or placebo
formulations, had not discontinued during the initial 3-year study,
and who agreed to participate. The recruited women in the US
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+  +   +     +     + + +
 + +   +     +     +  +   +
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*277subjects were randomised to quadrivalent vaccine. One subject withdrew consent prior to vaccination.
(day 1 to 
month 7)
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(day 1 to 
month 7)
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(months 7 – 36)
Figure 1 Trial design. Follow-up time for each woman in each study phase varies dependent on when she completed the last study visit. Discontinuations
through month 36 can be found in Villa et al (2005).
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swere not offered the possibility of enrolling in the extension phase
as they were largely from universities and were finishing school,
thus making this 2-year extension impractical for them.
This report presents the cumulative efficacy and immunogeni-
city results for all subjects who were randomised and vaccinated
with low-dose quadrivalent HPV vaccine or placebo, through the
extension period. Figure 1 shows the study design for the low-dose
formulation and placebo, including the extended follow-up phase.
Study vaccine
The quadrivalent vaccine consisted of a mixture of four
recombinant HPV type-specific VLPs composed of the L1 major
capsid proteins of HPV types 6, 11, 16, and 18 synthesised in
Saccharomyces cerevisiae (Lowe et al, 1997; Koutsky et al, 2002;
Ault et al, 2004). The low dose formulation is comprised of 20mgo f
HPV 6 VLP, 40mg of HPV 11 VLP, 40mg of HPV 16 VLP, and 20mg
of HPV 18 VLP, formulated with 225mg of aluminium adjuvant in
a total carrier volume of 0.5ml. The four VLP types were purified
and adsorbed onto amorphous aluminium hydroxyphosphate
sulphate adjuvant (AAHS). The placebo contained the same
adjuvant and was visually indistinguishable from vaccine.
Clinical follow-up
During the initial 3-year study, a 0.5-ml dose of quadrivalent
vaccine or placebo was administered by intramuscular injections
at day 1, month 2, and month 6. A gynaecological examination was
conducted at day 1 and at months 7, 12, 24, and 36. A ThinPrept
Pap test (Cytyc, Boxborough MA, USA) and external genital, lateral
vaginal, and cervical swabs for HPV DNA testing were obtained at
day 1 and at months 7, 12, 18, 24, 30, and 36. External anogenital
and vaginal lesions noted during the study were biopsied. Serum
samples were obtained at day 1 and months 2, 3, 6, 7, 12, 18, 24, 30,
and 36. In the extension, 241 subjects from Brazil and the Nordic
countries underwent two further years of follow-up. Subjects
enrolled in the extension phase had additional follow-up visits at
months 54 and 60, which included gynaecologic examination,
cervicovaginal sampling for HPV DNA, serum anti-HPV and Pap
testing (Figure 1).
Laboratory analyses
All Pap Testing and histologic evaluations were performed within
the study. Pap tests were read using The Bethesda 2001 System
(Solomon et al, 2002). Subjects referred for colposcopy had
discrete areas of abnormality biopsied using separate instruments.
All biopsies were processed independently to avoid HPV DNA
contamination. Biopsies were first read for clinical management by
pathologists at a central laboratory (Diagnostic Cytology Labora-
tories, Indianapolis, IN, USA) and then read for end point
determination by a blinded panel of four pathologists (Villa et al,
2005). HPV 6, 11, 16, and/or 18 infection was defined using HPV
DNA PCR and serology. Swabs, biopsy fragments and, later, tissue
thin sections cut adjacent to sections used for histopathology were
used for HPV DNA detection using HPV 6-, 11-, 16-, or 18-specific
L1, E6, and E7 primers in HPV Multiplex Real-Time PCR assays
(Villa et al, 2005). Serum anti-HPV 6, 11, 16, and 18 immuno-
globulin levels were measured using a competitive Luminex
immunoassay (cLIA), which were reported in arbitrary units
(milli-Merck Units per millilitre or mMU/ml) relative to the
standard curves generated for each individual HPV type (Opalka
et al, 2003). An audit conducted by Merck Research Laboratories
concluded that there was a deviation from the standard operating
procedure (SOP) for testing a subset of serum samples from the
protocol. Approximately, 0.1% of day 1 serology results and 0.4%
of postvaccination serology results were determined to have been
tested outside of the SOP. All day 1 serum samples that were tested
out of compliance with the SOP were reanalysed. The remaining
nonconformant test results were removed from the database.
Primary case definition
The study’s efficacy objective was to evaluate the impact of the
quadrivalent HPV L1 VLP vaccine with respect to the composite
end point of persistent HPV 6-, 11-, 16-, or 18-related persistent
infection or cervical or external anogenital or vaginal disease, as
compared to placebo. The persistent infection component of the
primary efficacy end point was defined as follows: the same
vaccine-HPV-type DNA detected in cervicovaginal samples
collected at two or more consecutive visits (required to be at least
4 months apart unless at least one sample was tissue diagnosed as
cervical, vaginal, or vulvar disease by the Pathology Panel) or
vaccine-HPV-type DNA detected in a sample collected during the
last visit before being lost-to-follow-up. Vaccine-HPV-type-related
disease was defined as a tissue sample diagnosed by consensus of
the Pathology Panel as cervical intraepithelial neoplasia (CIN),
adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia
(VIN), vaginal intraepithelial neoplasia (VaIN), external genital
warts or cervical, vulvar, or vaginal cancer with vaccine-HPV-type
DNA detected in tissue from, or a swab of, the same lesion and in
cervicovaginal samples obtained at the visit antecedent to the
biopsy visit. The latter condition was not required if vaccine-HPV-
type DNA was detected in biopsy thin sections.
Statistical analysis
The analyses presented here were conducted based on an interim
frozen file created using a visit cutoff date of 13 February 2006. The
interim frozen file was generated for an FDA Advisory Committee
meeting. At the time of the interim frozen file, 226 out of 241 (94%)
of subjects had complete data through month 60 that was available
for analysis. The primary analysis of efficacy was conducted in
type-specific perprotocol populations which consisted of subjects
who were PCR and seronegative to HPV 6, 11, 16, or 18 at
enrolment, remained PCR-negative to the same vaccine-HPV-
type(s) (to which they were naı ¨ve at enrolment) through 1 month
postdose three, received three doses of vaccine or placebo within 1
year, and did not violate the protocol. For example, to be eligible
for the perprotocol population for HPV 16-related end points, a
subject had to be both HPV 16 seronegative and HPV 16 DNA-
negative by PCR at enrolment, and remain HPV 16 DNA-negative
through 1 month postdose three. Prevalent or incident infection
with HPV 6, 11, or 18 was not an exclusion criterion for HPV 16-
related end points.
Follow-up for case ascertainment in the perprotocol population
started 1 month postdose three. Vaccine efficacy (VE) was defined
as 100% (1 (risk of becoming a case in the vaccine group/risk of
becoming a case in the placebo group)). An exact conditional
procedure was used to evaluate VE under the assumption that the
numbers of cases in the vaccine and placebo groups are
independent Poisson random variables. The number of cases in
the vaccine group follows a binomial distribution, which is
conditional on the total number of cases in the two vaccination
groups combined being fixed. This conditional binomial distribu-
tion which accounts for any differential follow-up was used as the
basis for calculating the point and exact 95% 2-sided confidence
interval (CI) estimates of VE (Chan and Bohidar, 1998). Each
subject’s follow-up time was computed by calculating the number
of person years between the specified starting time point and the
date she became a case, or the date she underwent definitive
therapy (cervical end points only) or her final visit date (for
noncases). If a subject developed more than one end point, her
date of becoming a case was the date at which the first end point
was detected.
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sSupportive prespecified analyses were conducted in a modified-
intention-to-treat (MITT) population that included all subjects
who were naı ¨ve to the relevant HPV type(s) at enrolment and had
received at least one vaccination. Protocol violators were included.
Follow-up for case ascertainment in the modified-intention-
to-treat population started 30 days after the first vaccination.
Anti-HPV 6, 11, 16, and 18 responses were measured in
quadrivalent vaccine recipients who were seronegative to the
relevant HPV type(s) at day 1 and remained PCR-negative to the
same HPV type(s) through month 60, and who had serology data
at month 60. Anti-HPV 6, 11, 16, and 18 responses were also
measured in placebo recipients who were seropositive and PCR-
negative to the relevant HPV type at day 1 and who had serology
data at month 60.
Role of the funding source
The studies were designed by the sponsor (Merck and Co., Inc.) in
collaboration with clinical site investigators. The sponsor collected
the data, monitored the conduct of the study, performed the
statistical analysis and coordinated the writing of the manuscript
with all authors. Data were unblinded for statistical analyses after
the data were screened for accuracy and completeness, protocol
violators were identified, and the databases were locked for the
primary analysis at month 36 (Villa et al, 2005). In the extension,
the subject and the investigator, study site personnel, laboratory
personnel conducting the clinical assays, and the Pathology Panel
used in end point adjudication remained blinded to vaccination
group. The authors were actively involved in data analysis and
interpretation, and approved the final manuscript. All authors
vouch for the veracity and completeness of the data and the data
analyses.
RESULTS
A total of 552 women were randomised to receive either
quadrivalent HPV vaccine or placebo (Figure 1). Among these
subjects, 241 women from Brazil and the Nordic countries were
enrolled in the extended follow-up study. Baseline characteristic
were similar between treatment groups in both the overall cohort,
and among subjects with extended follow-up (Table 1). As of the
time of this report, 226 of 241 extension subjects completed the
study through month 60. Two women in the quadrivalent vaccine
group and six women in the placebo group discontinued the study
before month 60 (Figure 1). Seven subjects had not completed the
month 60 visit. Among those with a month 60 visit, the average
time from the first vaccination was 5.03 years.
High sustained VE against persistent infection and disease was
observed through 5 years postenrolment (Table 2). In the
perprotocol efficacy analysis (all subjects through 3 years and
extension subjects through 5 years), 45 of the total 47 cases of HPV
6-, 11-, 16-, or 18-related persistent infection were observed in the
placebo cohort. Among quadrivalent vaccine recipients, there was
one case of HPV 16 DNA detection at the last visit before loss to
follow-up (month 36), and one case of verifiable persistent
infection attributed to HPV 18 infection. For this subject, HPV
18 DNA was detected at months 12 and 18 only. Subsequent time
points tested HPV 18 DNA-negative. Both of these subjects in the
quadrivalent vaccine group were cases in the initial 3-year efficacy
analysis (Villa et al, 2005). Therefore, during the extension phase,
all new cases of persistent infection (11 total) were observed in the
placebo cohort. Through 5 years, in the perprotocol population,
there were no cases of HPV 6-, 11-, 16-, or 18-related CIN or
Table 1 Summary of subject characteristics by vaccination group at
enrolment
Overall cohort
Subjects enroled in
protocol extension
Vaccine
(n¼277)
Placebo
(n¼275)
Vaccine
(n¼114)
Placebo
(n¼127)
Mean age (years) 20.2 20.0 20.5 20.3
Range (years) 16–23 13
a–23 16–23 16–23
Ethnic origin
Asian 7 (2.5%) 11 (4.0%) 0 (0%) 1 (0.8%)
Black 25 (9.0%) 18 (6.5%) 14 (12.3%) 15 (11.8%)
Hispanic 14 (5.1%) 20 (7.3%) 3 (2.6%) 3 (2.4%)
White 216 (78.0%) 214 (77.8%) 88 (77.2%) 99 (78%)
Other 15 (5.4%) 12 (4.4%) 9 (7.9%) 9 (7%)
Region
USA 125 (45.1%) 126 (45.8%) NA NA
Brazil 94 (34.0%) 93 (33.8%) 72 (63.2%) 79 (62.2%)
Nordic 58 (20.9%) 56 (20.4%) 42 (36.8%) 48 (37.8%)
aOne subject was 13 years and one subject was 15 years at the time of enrolment.
Table 2 Analysis of efficacy of the quadrivalent HPV vaccine against HPV 6-, 11-, 16-, or 18-related persistent infection or disease in the perprotocol
population through 5 years postenrolment (all subjects through 3 years and extension subjects through 5 years)
Vaccine Placebo
End point
a n Cases Women-years at risk Rate
b n Cases Women-years at risk Rate
b Efficacy (%) 95% CI (%)
Infection or disease 235 2 767.9 0.3 233 46 747.4 6.2 95.8 (83.8, 99.5)
Infection 235 2 764.7 0.3 233 45 749.7 6.0 95.6 (83.3, 99.5)
Disease 235 0 771.9 0.0 233 6 796.4 0.8 100.0 (12.4, 100.0)
CIN 1-3 235 0 755.5 0.0 233 3 774.9 0.4 100.0 (o0.0, 100.0)
Condyloma 235 0 771.1 0.0 233 3 796.2 0.4 100.0 (o0.0, 100.0)
End points by HPV type
HPV 6-related 214 0 700.7 0.0 209 17 702.7 2.4 100.0 (75.7, 100.0)
HPV 11-related 214 0 700.7 0.0 209 3 712.4 0.4 100.0 (o0.0, 100.0)
HPV 16-related
c 199 1 663.3 0.2 198 28 637.5 4.4 96.6 (79.2, 99.9)
HPV 18-related
c 224 1 732.7 0.1 224 11 753.9 1.5 90.6 (35.6, 99.8)
n¼no. of subjects included in the perprotocol population who had at least one follow-up visit.
aA subject appears only once within each row. A subject may appear in more than
one row.
bCases per 100 woman years at risk.
cAmong quadrivalent vaccine recipients, there was one case of HPV 16 DNA detection before loss to follow-up (month 36), and a
single case of verifiable persistent infection attributed to HPV 18 infection. For this subject, HPV 18 DNA was detected at months 12 and 18 only. The bold values are the data
for the primary composite end point for which the study was designed and powered.
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sexternal anogenital or vaginal lesions in vaccine recipients, and six
cases in placebo recipients (efficacy¼100%; 95% CI: 12.4–100%).
Statistical significance was not reached for the disease end points
separately. Thus, among quadrivalent vaccine recipients, there
were no breakthrough cases of infection or disease during the
extended follow-up period.
High efficacy through 5 years was also observed when
considering only study data from those perprotocol subjects who
were eventually enrolled in the extension phase (104 vaccine
subjects vs 120 placebo subjects). Among the 224 extension
subjects, there was one case of infection in quadrivalent vaccine
recipients (HPV 18 DNA detection at months 12 and 18, vide
supra) and 22 cases of persistent infection or disease in placebo
recipients (efficacy¼95.1%; 95% CI: 69.4–99.9%).
We also analysed VE in a MITT population that included subjects
who were HPV 6, 11, 16, or 18 naı ¨ve at enrolment and that received
at least one dose of vaccine or placebo, regardless of general protocol
violations (Table 3). Such subjects approximate the population of
adolescent and young adult women who received at least one dose of
the vaccine before exposure to an HPV type targeted by the vaccine.
The observed efficacy against infection was 93.5% (95% CI: 82.5–
98.3%). No cervical, vulvar, or vaginal disease or genital warts due to
HPV 6, 11, 16, or 18 was observed in quadrivalent vaccine recipients
(efficacy¼100%; 95% CI: 55.3–100%).
As there was an 18-month gap between month 36 (the last visit
under the original protocol) and month 54 (the first visit in the
extension phase) there was a small chance that cases of persistent
infection may have occurred in this window which were not
captured within the study. A sensitivity analysis was thus
conducted to estimate the impact of the 18-month gap on VE.
The sensitivity analysis involved modification of the definition of
persistent infection such that an extension subject with a single
time positive infection detected at month 36 or 54 without
confirmation of persistence (including samples from any un-
scheduled biopsies between month 36 and month 54), was
additionally counted as a case of persistent infection. The
definition of the disease component did not change. Using this
modified definition, four placebo and two vaccine recipients were
conservatively counted as additional cases of persistent infection
due to vaccine-type DNA detected at a single visit at either month
36 or 54, resulting in a total of four cases in the vaccine group and
50 cases in the placebo group. No subject who had an unscheduled
biopsy performed between months 36 and 54 had vaccine-type
DNA detected in that biopsy sample. No disease cases caused by
vaccine HPV types were added in the sensitivity analysis. The VE
estimate from the sensitivity analysis was 92% (95% CI: 78–98%).
Vaccine-induced anti-HPV GMTs were measured using a
competitive assay, which measures the antibody response to
known neutralising epitopes. This provides a specific measure of
immunogenicity that is clinically related to protection against HPV
infection. At month 7 (1 month after dose three) anti-HPV GMTs
among quadrivalent vaccine recipients were substantially higher
than GMTs among placebo-recipients with a previous history of
natural HPV infection (Table 4). Though the number of placebo
subjects who were infected before vaccination is too small to make
meaningful comparisons, at month 60, vaccine-induced immune
responses appear to remain at or above the GMTs observed in
placebo-treated women who mounted an immune response
presumably associated with clearance of HPV infection.
DISCUSSION
The present study demonstrates sustained long-term efficacy and
immunogenicity for a multivalent vaccine targeting the HPV types,
which are responsible for a significant proportion of anogenital
cancers and genital warts. Over 5 years of follow-up, the incidence
of HPV 6-, 11-, 16-, or 18-related disease was reduced by 100%
among women who received at least one dose (MITT population),
compared with placebo recipients. A persistent and measurable
immune response equal to or greater than that observed during
natural infection was maintained through 5 years. Although the
study was not originally powered to conduct analyses of VE for the
disease end points, separately phase III studies conducted in
418000 women have shown this quadrivalent vaccine to be 100%
effective against cervical, vaginal, and vulvar precancerous lesions
and genital warts through 2 years of follow-up in the perprotocol
efficacy population (Sattler, for the FUTURE I Investigators, 2005;
Skjeldestad, for the FUTURE II Steering Committee, 2005), providing
encouraging information about the potential long-term efficacy of
this vaccine in protecting against clinically relevant disease.
Importantly, there were no breakthrough cases of disease
through the entire 5-year study. The design of the study allowed
for the full ascertainment of HPV 6-, 11-, 16-, and 18-related
genital disease. Both the external genitalia and cervicovaginal tract
were sampled. Subjects underwent external genital and cervicova-
ginal examination at 6-month intervals through 36 months, and
then at months 54 and 60. It should be noted that all subjects
Table 3 Analysis of efficacy of the quadrivalent HPV vaccine against HPV 6-, 11-, 16-, or 18-related persistent infection or disease in the modified
intention-to-treat population through 5 years postenrolment (all subjects through 3 years and extension subjects through 5 years)
Vaccine Placebo
End point
a n Cases Women-years at risk Rate
b n Cases Women-years at risk Rate
b Efficacy (%) 95% CI (%)
Infection or disease 266 4 945.0 0.4 263 59 879.5 6.7 93.7 (83.0, 98.3)
Infection 256 4 939.0 0.4 254 58 880.0 6.6 93.5 (82.5, 98.3)
Disease 266 0 951.9 0.0 263 10 953.3 1.0 100.0 (55.3, 100.0)
CIN 1-3 258 0 930.6 0.0 256 7 928.5 0.8 100.0 (30.8, 100.0)
Condyloma 265 0 950.4 0.0 261 4 955.0 0.4 100.0 (o0.0, 100.0)
End points by HPV type
HPV 6-related 242 0 860.7 0.0 242 22 854.9 2.6 100.0 (81.9, 100.0)
HPV 11-related 242 0 860.7 0.0 242 4 868.9 0.5 100.0 (o0.0, 100.0)
HPV 16-related
c 225 3 819.6 0.4 229 34 779.0 4.4 91.6 (73.3, 98.4)
HPV 18-related
c 253 1 897.8 0.1 253 12 904.2 1.3 91.6 (43.3, 99.8)
n¼no. of subjects included in the modified-intention-to-treat population who had at least one follow-up visit.
aA subject appears only once within each row. A subject may
appear in more than one row.
bCases per 100 woman years at risk.
cDescription of cases among quadrivalent vaccine recipients: one case of confirmed persistent infection with
HPV 18 DNA detected at months 12 and 18 only (same subject as perprotocol analysis); one case of confirmed persistent infection with HPV 16 DNA detected at months 7, 12,
and 18; and two cases of HPV 16 DNA detected at the last visit on record (months 2 and 36 (same subject as perprotocol analysis)). The bold values are the data for the primary
composite end point for which the study was designed and powered.
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sunderwent a mandatory colposcopy at month 36, increasing the
likelihood that cervical disease, if present, would be detected.
Unscheduled biopsies during the 18-month gap were included in
the analysis, and showed that no HPV 6-, 11-, 16-, or 18-related
disease was observed among quadrivalent vaccine recipients. In
addition, there were no breakthrough cases of infection during the
extension phase. All of the 11 cases observed during the extension
were in the placebo group (perprotocol analysis). These data
support the high observed 5-year duration of efficacy.
The WHO defines persistent infection as detection of the same
HPV DNA in cervicovaginal specimens obtained in follow-up visits
6–12 months apart in women who are naive for the relevant type
at baseline (Pagliusi and Aguado, 2004). An additional strength of
the study is the conservative definition of persistent infection,
which included all cases where HPV DNA was detected at two
consecutive visits required to be at least 4 months apart unless at
least one sample was tissue diagnosed as cervical, vaginal or,
vulvar disease by the Pathology Panel. In addition, subjects with
HPV DNA detected at the last visit on record were conservatively
counted as cases of persistent infection. Our sensitivity analysis
included cases of single-time infection. VE remained high when
including such cases. In the perprotocol population, when
excluding cases due to HPV DNA detection at the last visit on
record, only one subject in the quadrivalent vaccine group had
vaccine-type DNA detected at two consecutive visits (months 12
and 18 only) through 5 years of follow-up.
A potential limitation of the present study is the relatively small
number of women who were enrolled in the extension phase. In
addition, the study did not follow American women through the
extension period due to the predicted difficulties associated with
maintaining enrolment for two additional years, as most were
recruited from college campuses. However, a previous study of the
monovalent HPV 16 component of the quadrivalent vaccine
followed 2391 American women through 4 years (Mao et al,
2006). In this study, VE in the perprotocol population was 100%
for preventing HPV 16-related cervical dysplasia of any grade
severity, suggesting that VE is not affected by race or region, and
should remain equally high in the US population. Another
potential limitation of the current study is the 18-month gap that
ensued between month 36 and month 54. A previous study has
shown that the median time to clearance of persistent HPV 16
infection is 20.7 months (Mao et al, 2006). Thus, there was a
potential for bias with respect to efficacy estimates for persistent
infection, as HPV DNA detection at month 36 could be due to
transient infection, contamination, or true persistent infection,
which may have cleared by month 54. It should be noted that the
observed VE against persistent infection (95.5%) is higher than
that previously reported in the 3-year analysis published by Villa
et al (2005) (89%). Three subjects in the primary 3-year analysis
had HPV 16 DNA detected at the last visit on record (month 36).
Two of these subjects had extended follow-up and a subsequent
month 54 swab which was DNA-negative. Consequently, there was
no observed persistence of infection, although the possibility that
infection was present between months 36 and 54 cannot be ruled
out. It has been established that histologic changes of the cervix
become apparent within 1.5 years of initial HPV infection (Sattler,
for the FUTURE I Investigators, 2005) and genital warts may
develop even faster (Winer et al, 2005). Thus, even with the 18-
month gap, the present study was not limited in its ability to detect
clinically relevant HPV-related disease.
Ideally, a prophylactic HPV vaccine would be given to young
adolescents before the initiation of sexual activity since HPV is
transmitted through genital contact. Our primary analysis
considered a susceptible population of women who were naı ¨ve to
vaccine-HPV-types at baseline. All sexually active individuals are
at risk for HPV infection and disease, including those who do not
engage in penetrative sexual intercourse. A recent study has shown
the 24-month cumulative incidence of HPV infection among
virgins before initiation of penetrative sexual intercourse was
15.3% (Winer et al, 2003). The fact that men and women remain at
risk of HPV infection as long as they are sexually active, in
combination with the lack of effective means to prevent HPV
infection in sexually active people, requires vaccine-induced
protection to be long-lived. Recently, a bivalent HPV 16/18 vaccine
showed high efficacy against persistent HPV 16 or 18 infections
through 4.5 years (Harper et al, 2006). In the present study, we
have shown that a quadrivalent HPV vaccine formulated on
proprietary aluminium adjuvant to be highly efficacious and
immunogenic through 5 years. Vaccine-induced responses at
month 60 remained at or above the response level seen by natural
infection. The vaccine-induced immune response appears highest
for HPV 16, however, as the monoclonal antibodies used in the
Table 4 Anti-HPV 6, 11, 16, and 18 geometric mean titres through 5 years (extension subjects only)
Vaccine recipients who were baseline seronegative and
PCR-negative for a specific HPV type
a
Placebo recipients who were baseline seropositive and
PCR-negative for a specific HPV type
n GMT (mMU/ml) 95% CI n GMT (mMU/ml) 95% CI
Month 7
HPV-6 77 559.7 (466.5, 671.5) 9 31.3 (14.9, 65.7)
HPV-11 83 642.4 (530.3, 778.2) 2 342.7 N/A
HPV-16 78 3889.1 (3147.1, 4806.1) 9 42.0 (13.8, 128.3)
HPV-18 82 755.5 (582.3, 980.1) 7 36.4 (12.3, 107.5)
Month 36
HPV-6 77 88.1 (70.5, 110.0) 9 28.9 (14.5, 57.6)
HPV-11 79 78.0 (61.5, 99.0) 2 219.2 N/A
HPV-16 78 441.3 (350.3, 556.1) 9 21.5 (o12, 64.3)
HPV-18 82 50.5 (36.7, 69.5) 7 24.0 (9.9, 58.0)
Month 60
HPV-6 77 66.5 (52.3, 84.6) 9 30.5 (14.9, 62.5)
HPV-11 83 67.6 (51.1, 89.3) 2 150.4 N/A
HPV-16 78 395.4 (303.2, 515.7) 8 16.0 (o12, 52.2)
HPV-18 82 43.7 (30.8, 62.1) 7 32.7 (9.3, 115.0)
aSubjects in the perprotocol population who were PCR-negative and seronegative to the relevant HPV type at day 1 and remained PCR-negative to the same HPV type through
month 60.
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scompetitive assays each recognise type-specific epitopes, one
cannot draw conclusions with regard to the relative immunogeni-
city of the four VLP components in the vaccine. The scale of the
competitive immune response is dependent upon the particular
attributes of each monoclonal antibodies, the epitope that they
recognise, and their relationship to the standard curve generated
for each individual HPV type tested. Other studies have shown that
quadrivalent vaccine-induced responses in 10- to 15-year-old girls
are substantially higher than the vaccine-induced responses
observed in 16- to 23-year-old women (Block et al, 2006). Thus,
it is likely that administration of quadrivalent HPV vaccine to
female adolescents before sexual debut will induce long-term
protective efficacy. Sexually active young women with few lifetime
sex partners, similar to women enrolled in this trial, will also
benefit from vaccination.
This study has demonstrated that a prophylactic quadrivalent
HPV vaccine induced high-titre anti-HPV serum antibody levels
and was highly effective through 5 years for prevention of
persistent infection, neoplasia, and genital warts caused by HPV
6, 11, 16, and 18. This duration supports vaccination of adolescents
and young adults, which is expected to greatly reduce the burden
of cervical and other anogenital cancers, low- and high-grade
intraepithelial neoplasias and genital warts.
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